Widely recognised in the industry for our R&D capabilities, C&O is one of the leading pharmaceutical companies in China with the expertise to provide contract research (CRO) services – targeted at the growing number of international pharmaceutical companies seeking to outsource their R&D activities to China.

Our R&D team comprising more than 80 in-house researchers, they are specialists who have been hand-picked for their expertise in different research fields. Currently, we have two R&D centres which are located in Nanjing and Shanghai, being the hub of China’s pharmaceutical industry. We also collaborate with renowned universities, R&D institutions and companies to boost our R&D capabilities. Examples of our strategic partners include China Pharmaceutical University (CPU), Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), Sichuan Agricultural University, Optimer Pharmaceuticals, Inc., Pharmco International, Incorporated and other independent researchers in the US.

We have a strong pipeline of drugs covering acute medical areas such as anti-infection and anti-inflammatory, anti-HBV, anti-cancer, anti-tuberculosis, anti-obesity, gastrointestinal drugs and drugs for the ageing.

Currently, we have more than 50 new products in the pipeline, about a quarter of them are potential patented drugs. We are also in the midst of developing over 10 new compounds with potential for international patent applications.